Allisartan

Drug Profile

Allisartan

Alternative Names: Allisartan isoproxil; Shun Li Tan®; Xinlitan

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Allist Pharmaceuticals
  • Developer Allist Pharmaceuticals; Shenzhen Salubris Pharmaceuticals
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 31 Mar 2010 Allist Pharmaceuticals completes a phase III trial in Hypertension in China (ChiCTR-TRC10000885)
  • 31 Jan 2010 Allist Pharmaceuticals completes a phase II trial in Hypertension in China (ChiCTR-TRC10000886)
  • 30 Apr 2009 Allist Pharmaceuticals initiates enrolment in a phase II trial for Hypertension in China (ChiCTR-TRC10000886)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top